Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MITF | O75030 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977495 | 0.88 | MEN1 (0.47) | KMT2AP2RX4ALDH1A1 | |
| SCHEMBL4875253 | 0.85 | KMT2A (0.71) | KMT2AP2RX4PKMTHRBLMNA | |
| SCHEMBL4595405 | 0.84 | KMT2A (0.59) | KMT2AP2RX4THRBLMNACFTR | |
| SCHEMBL4594276 | 0.82 | TYMS (0.45) | KMT2AP2RX4ALDH1A1 | |
| SCHEMBL4593864 | 0.79 | KMT2A (0.62) | KMT2AP2RX4PKMTHRBLMNA | |
| SCHEMBL693976 | 0.77 | HSPB1 (0.55) | KMT2APKMTHRBLMNAMAPT | |
| SCHEMBL4595516 | 0.75 | KIF11 (0.57) | KMT2ALMNAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL12952828 | 0.73 | CA12 (0.61) | KMT2ALMNAMAPTNPSR1TP53 | |
| SCHEMBL1242136 | 0.72 | PGR (0.52) | KMT2ALMNAMAPTNPSR1HTT | |
| SCHEMBL1241412 | 0.72 | HSPB1 (0.65) | KMT2ALMNAMAPTNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1874733-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111346-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | TRPV1, TRPA1, P2RX3 | KMT2A 4782/4885P2RX4 4/4885PKM 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.